See oncology risk before it becomes a claim.
Risk-bearing oncology groups and health plans learn about care gaps, pathway deviations, and delayed treatment starts from claims, months after the fact. Arca tracks every patient against the treatment plan in real time, closes gaps as they open, and measures pathway adherence, time to treatment, and utilization across the population.
Same case, same treatment, started 97 days earlier. Every four weeks a cancer treatment waits adds 6–8% to mortality.
The operating layer for value-based oncology care.
For a risk-bearing oncology group: every patient against the treatment plan, every open step owned, and pathway adherence, time to treatment, and utilization computed from the cases themselves. For a health plan: prospective visibility into care, ahead of the claims. Each patient's pathway status, open care gaps, and treatment start, with the evidence behind them. One record, read by both.
Know which patients are off track, and get them back on.
Every active episode against its treatment plan: where the patient is, how long since the decision, and whether the next step has happened. A stalled authorization or an unscheduled scan is flagged, assigned, and closed with evidence, and the population view updates as it happens.
Synthetic cases. Patient details invented.
The treatment plan, tracked to completion.
What was decided, who owns each next step, when it is due, and whether it happened. One patient, three moments.
The plan becomes a set of dated commitments.
One structured entry at the moment of the decision: the recommendation, its pathway status, and each next step with an owner and a due date.
A step that goes quiet is flagged.
Each step counts its own days. Past its due date it flags on the navigator's list and the program view until someone closes it with evidence.
Population performance, computed from the record.
Time to treatment, pathway adherence, and closed care gaps, from the cases themselves. The same figures serve the accreditor and the health plan.
Synthetic case and figures. Patient details invented.
What a risk-bearing group gains, per patient per month.
Medicare's Enhancing Oncology Model pays $110 per patient per month for coordination, up 57% in 2025, and shares savings against each practice's own historical spending. Inpatient care is $5,493 of a $36,190 chemotherapy episode, and 35 to 67% of those admissions are avoidable. A group that sees every episode while it is open earns the payment and keeps the avoided spend. In the model's first period, 79% of the 43 practices came in under their historical spending.
For a risk-bearing oncology group
The coordination payment on every enrolled patient. Shared savings measured against your own baseline. Fewer avoidable admissions and ED visits inside your total cost of care, and treatment that starts weeks sooner.
For a health plan
Avoided acute care across the delegated population. Pathway adherence and care gaps visible while the episode is open, months ahead of the claim. A documented treatment plan with its evidence attached, approved on receipt.
CMS Enhancing Oncology Model MEOS rate, 2025; CMS Innovation Insight, first EOM reconciliation, Aug 2025; OCM service-specific costs and 2.1% episode reduction, Abt; OP-35 literature, 35 to 67% avoidable. The reachable band assumes 20 to 30% capture. The full figures, with sources.
Six weeks to the first patients on Arca.
Configuration in week one. One program running on Arca alongside your current process by week three. Care-gap tracking and the first population report after that.
Epic, Cerner, and Athena feeds are supported. A program can start on referrals alone.
Tell us where your oncology risk sits.
Which contracts, which sites, and who manages the follow-through today. We reply within two business days with how Arca would run alongside them, starting with one program.